We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

August 20, 2021

How has COVID-19 Shaped DTx for the Mental Health Market?

Commentary
Nadia Worgan
&

How has COVID-19 Shaped DTx for the Mental Health Market?

The prevalence of mental health conditions had been relatively stable before 2020, however, this trend changed at the onset of the COVID-19 pandemic. Globally, the mental health of the population deteriorated. According to the OECD, the prevalence of both anxiety and depression increased rapidly around the world, and in some countries, it doubled since the start of the pandemic, especially during periods of high COVID-19 deaths and strict regulations. These conditions affect one in five people, but between 30-40% of those needing treatment for these disorders do not receive it. However, DTx can serve as a mitigating factor for this trend.

During the pandemic, the delivery of these essential mental health services was disrupted and so health care professionals quickly needed to change their modes of delivery. Mitigation strategies for these disruptions included switching to remote care, digital platforms and telemedicine

Digital Therapeutics (DTx) serves as a potential solution for this need to address the growing demand for mental health services and deliver personalised treatment interventions. The treatment outcomes for mental health are intrinsically subjective and so digital tools can help to improve this by collecting and monitoring digital biomarkers (consumer-generated physiological and behavioural measures). 

Our HealthXL insights show that a  successful route to market for DTx mental health solutions is through partnerships. Employer and insurance partnerships have shown to be successful routes to market, and following this, pharmacy and hospital partnerships also hold great potential. However, as DTx for mental health is a relatively new solution, there are some key challenges in adopting this such as: low rates of reimbursement, building significant evidence to support their clinical benefits, patient engagement and finally, physician time and awareness. 

Despite these challenges, many companies have seen the potential of the mental health DTx market and are becoming increasingly active in this space by launching new platforms or by making significant investments in this area.

Ro, a direct-to-consumer virtual care company, is rolling out a new mental health platform called Ro Mind. This will initially focus on generalised anxiety disorder (GAD) and major depressive disorder (MDD). This service offers patients access to US-licensed providers who can, if appropriate, diagnose and prescribe FDA-approved prescription treatments for anxiety and depression. Ro Mind also works with patients to manage these treatments and track their progress on a regular basis. If patients are prescribed medication, they are supported by Ro’s nationwide pharmacy network. Ro pharmacies coordinate care with providers to adjust dosing and ensure patients receive the appropriate medication when needed. Ro also supports patients by offering psychoeducation through virtual sessions at no extra cost. Ro is also planning to launch more services, including individual and group therapy.

Happify Health has announced the launch of Ensemble, this is the first and only transdiagnostic prescription digital therapeutic for the treatment of patients who have GAD or MDD. Ensemble is prescribed by a clinician to treat these disorders, it delivers skills training based on cognitive behavioural therapy (CBT), mindfulness and related forms of behavioural science-based techniques and activities designed to treat symptoms of MDD and GAD.

Amwell, a national telehealth leader, has recently acquired SilverCloud Health, a leading digital mental health platform. SilverCloud Health offers a range of digital cognitive behavioural health programs which are evidence-based and clinically validated. Their programs have shown results equivalent to face-to-face care for the one in five with diagnosable mental health conditions. Amwell will be able to leverage SilverCloud’s platform to expand its own behavioural health offerings and develop new digital specialty care programs. 

Woebot Health recently announced that they have closed a $90 million Series B funding round to advance their relational platform and digital therapeutics for mental health to meet the increasing global demand for these services.

In order to establish product integrity and confirm patient safety, all DTx products should adhere to the Industry Core Principles which are utilised as a guide for best practice to end users, clinicians and payors as they investigate the efficacy and safety of DTx products. These principles state that DTx products should publish clinical trial results, incorporating meaningful outcomes and peer-reviewed journals. They should be reviewed and cleared or approved by regulatory bodies as required to support product claims of risk, efficacy and intended use. The products should only make claims appropriate to clinical evaluation and regulatory status. DTx products should collect, analyse and apply real world evidence and product performance data. 

The current capacity for mental health services is buckling under the evident cumulative rise in demand for these services. Digital Therapeutics offer the ultimate solution by expanding capacity to offer these services via technology in a clinically effective and safe way, to reach more people who need support.

Are you interested in learning more about Digital Therapeutics for Mental Health? Join your peers at our upcoming digital health meeting on September 7th, 23rd and 28th.



We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: DTx last mile delivery: HCPs and Patient adoption (Part 2)

3rd February @ 10:45AM EDT

Are you struggling getting HCPs and/or patients to adopt your DTx products? Keep reading, this sprint is for you! Places are limited so apply now to join the second session of this series and discuss with other senior leaders, DTx last mile delivery.

Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: The Regulation of SaMD in the US

14th February @ 10:45AM EDT

Join us in this US-focused Masterclass led by Clay Anselmo and Bernhard Kappe, As they walk us through the regulation of SaMD in the US. Apply now to secure your place.

Featuring
Bernhard Kappe
Bernhard Kappe
Founder & CEO, Orthogonal
Clay Anselmo
Clay Anselmo
VP Quality Assurance and Regulatory Affairs, ENvizion
Featuring
Bernhard Kappe
Bernhard Kappe
Founder & CEO, Orthogonal
Clay Anselmo
Clay Anselmo
VP Quality Assurance and Regulatory Affairs, ENvizion
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx - Pharma partnerships

15th February @ 10:45AM EDT

Join us as we deep dive into DTx-Pharma partnerships, with a focus on how to monetize DTx within the traditional pharmaceutical business model. Apply now to connect with peers and hear from thought leaders in this space.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Mansa Shroff
Mansa Shroff
Head of Partnerships at WKD.SMRT
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Mansa Shroff
Mansa Shroff
Head of Partnerships at WKD.SMRT
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Webinar: DTx commercialisation models - Pharma Partnerships & D2C route

17th February @ 10:00AM EDT

Last month, we did a deep dive on the Employer route to market for DTx products. Join us this month as we look into other potential go-to-market strategies for Digital Therapeutics. Apply now to hear valuable insights from thought leaders in this space.

Featuring
Pierre Leurent
Pierre Leurent
CEO, Voluntis
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee
Featuring
Pierre Leurent
Pierre Leurent
CEO, Voluntis
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation

Masterclass: Clinical Trials Design for Digital Health products

31st January @ 10:45AM EDT

Join us in this Masterclass led by Click Therapeutics, as we discuss Clinical Trials Design for Digital Health Products. Our Masterclass sessions are the perfect opportunity to hear from thought leaders in the space and share your own thoughts and experiences.

Featuring
Shaheen Lakhan
Shaheen Lakhan
Chief Medical Officer , Click Therapeutics
Featuring
Shaheen Lakhan
Shaheen Lakhan
Chief Medical Officer , Click Therapeutics
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation

Digital tech for Trial Recruitment and Retention

2nd February @ 10:45AM EDT

Join our Digital Health Meeting led by Laura Gunn from Pharmstars as we discuss digital tech for Trial Recruitment and Retention. This is the perfect opportunity to connect with peers and meet new people working in this space.

Featuring
Laura Gunn
Laura Gunn
Managing Director at PharmStars
George Platings
George Platings
Market Development Specialist at uMotif
Featuring
Laura Gunn
Laura Gunn
Managing Director at PharmStars
George Platings
George Platings
Market Development Specialist at uMotif
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: DTx last mile delivery: HCPs and Patient adoption (Part 2)

3rd February @ 10:45AM EDT

Are you struggling getting HCPs and/or patients to adopt your DTx products? Keep reading, this sprint is for you! Places are limited so apply now to join the second session of this series and discuss with other senior leaders, DTx last mile delivery.

Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

Digital Health Solutions with the greatest impact in cancer patients' lives

8th February @ 10:45AM EDT

How can Digital Health improve cancer patients’ lives? Are you working in this industry? Keep reading, this meeting is for you. Join us as we discuss current Digital Health products in oncology and the unmet/gaps need to be addressed.

Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.